Targeted therapies for lung cancer: how did the game begin?

Breathe (Sheff). 2016 Jun;12(2):177-9. doi: 10.1183/20734735.006316.

Authors

Nikolaos I Kanellakis¹, Tiago Jacinto², Ioannis Psallidas¹

Affiliations

¹ Oxford Centre for Respiratory Medicine and Oxford Respiratory Trials Unit, Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Respiratory Medicine Laboratory, Nuffield Dept of Medicine, University Of Oxford, Old Road Campus, Oxford, UK.
² Instituto and Hospital CUF Porto, Porto, Portugal.; Centre for Research in Health Technologies and Information Systems, Faculty of Medicine, Porto, Portugal.

Abstract

Landmark studies on genetic alterations underlying NSCLC have led to tailored therapies http://ow.ly/4nq0Ps.